Pharmacogenomic considerations for customizing warfarin therapy in the orthopedic patient.
University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
Sonja
S
Rhee
Kelly
K
Walsh
Daniel
D
Lewis
George
G
Davis
Kelly M
KM
Smith
D000925:Anticoagulants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D005820:Genetic Testing; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics; D009985:Orthopedics / Q000379:methods*; D010347:Patient Care Planning; D010597:Pharmacogenetics; D054556:Venous Thromboembolism / Q000235:genetics / Q000517:prevention & control; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases